Dong-A ST Reports Q1 Sales of 169 Billion KRW and Operating Profit of 7 Billion KRW

Sales up 20.7%
Operating profit up 853.8%

On April 29, Dong-A ST announced that it recorded sales of 169 billion KRW and operating profit of 7 billion KRW in the first quarter of this year. Compared to the same period last year, sales increased by 20.7% and operating profit rose by 853.8%.

In the ETC (ethical drugs) segment, sales of Growtropin and Morititone grew. The addition of new products such as Jacuvo and Tanamin led to a 15.4% increase in sales compared to the same period last year. In the overseas business segment, sales of Can Bacchus (Cambodia) increased, and the addition of new products such as Imuldosa and Ecowin resulted in a 51.2% increase in sales compared to the same period last year.

In the R&D (research and development) segment, the autoimmune disease treatment Stelara biosimilar (biopharmaceutical generic drug) 'Imuldosa' received FDA (Food and Drug Administration) approval in the United States in October last year and is scheduled for launch in the US next month. Imuldosa obtained EC (European Commission) approval in December last year, was launched in Germany in January this year, and has been available in the UK and Ireland since March. It is scheduled to be launched sequentially in other European countries such as Spain and Italy.

The company is also conducting global Phase 2 clinical trials for DA-1241, a treatment for MASH (metabolic dysfunction-associated steatohepatitis) and type 2 diabetes, through its US subsidiary Metavia. Part 2 of the global Phase 1 clinical trial for the obesity treatment DA-1726 is also underway. In preclinical studies, DA-1241 demonstrated efficacy in improving fatty liver and liver fibrosis. Synergistic effects in improving liver fibrosis were also observed when used in combination with semaglutide, the active ingredient in Wegovy. The Alzheimer's treatment DA-7503 is currently undergoing Phase 1 clinical trials in Korea.

The company is also expanding next-generation modality drug development through the acquisition of Aptys, a company specializing in antibody-drug conjugates (ADCs). Aptys has developed 'AppClick', a third-generation ADC linker technology that enables site-selective drug conjugation. The preclinical study of DA-3501 (AT-211), a Claudin 18.2 ADC candidate targeting gastric and pancreatic cancers based on AppClick technology, has been completed. The company aims to initiate Phase 1 clinical trials in Korea within this year.

This content was produced with the assistance of AI translation services.